Homocysteine impairs the nitric oxide synthase pathway: role of asymmetric dimethylarginine.

@article{Sthlinger2001HomocysteineIT,
  title={Homocysteine impairs the nitric oxide synthase pathway: role of asymmetric dimethylarginine.},
  author={Markus C. St{\"u}hlinger and Philip S. Tsao and J H Her and Masumi Kimoto and Robert F. Balint and John P Cooke},
  journal={Circulation},
  year={2001},
  volume={104 21},
  pages={
          2569-75
        }
}
BACKGROUND Hyperhomocysteinemia is a putative risk factor for cardiovascular disease, which also impairs endothelium-dependent vasodilatation. A number of other risk factors for cardiovascular disease may exert their adverse vascular effects in part by elevating plasma levels of asymmetric dimethylarginine (ADMA), an endogenous inhibitor of nitric oxide synthase. Accordingly, we determined if homocysteine could increase ADMA levels. METHODS AND RESULTS When endothelial or nonvascular cells… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 323 CITATIONS, ESTIMATED 62% COVERAGE

Carotid restenosis is associated with plasma ADMA concentrations in carotid endarterectomy patients

  • Clinical chemistry and laboratory medicine
  • 2011
VIEW 5 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

Increased plasma asymmetric dimethylarginine (ADMA) levels in retinal venous occlusive disease

  • Clinical chemistry and laboratory medicine
  • 2008
VIEW 6 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

FILTER CITATIONS BY YEAR

1998
2019

CITATION STATISTICS

  • 20 Highly Influenced Citations

  • Averaged 12 Citations per year from 2017 through 2019

References

Publications referenced by this paper.
SHOWING 1-10 OF 38 REFERENCES

Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease

V Schachinger, MB Britten, AM. Zeiher
  • Circulation
  • 2001

Does ADMA cause endothelial dysfunction?

  • Arteriosclerosis, thrombosis, and vascular biology
  • 2000